Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Steps Up As AiCuris’ First Development Partner

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck partners with on AiCuris on letermovir and other antiviral candidates for human cytomegalovirus (HCMV), marking the first development deal for the German drug developer, spun out from Bayer in 2006.


Related Content

New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack
Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral
AiCuris GMBH & Co. KG


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts